Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran and rivaroxaban: results from the CRAFT study.

CONCLUSIONS: Prescription of VKAs had significantly declined since the introduction of NOACs. Patients treated with different OACs demonstrated a distinct baseline clinical profile. The highest risk of thromboembolic events and incidence of major bleedings were observed in patients on rivaroxaban in comparison to patients on VKAs and dabigatran. Among NOACs, patients treated with lower doses of dabigatran and rivaroxaban were older and had significantly higher risk of thromboembolic and bleeding events.
PMID: 29350386 [PubMed - as supplied by publisher]

Source: Polish Heart Journal - January 19, 2018 Category: Cardiology Authors: Balsam P, Ozierański K, Tymińska A, Żukowska K, Zaleska M, Szepietowska K, Maciejewski K, Peller M, Grabowski M, Lodziński P, Praska-Ogińska A, Zaboyska I, Kołtowski Ł, Kowalczuk A, Bednarski J, Filipiak KJ, Opolski G Tags: Kardiol Pol Source Type: research